|
業務類別
|
Biotechnology |
|
業務概覽
|
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial andoperational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform. |
| 公司地址
| One World Trade Center, Suite 8500, New York, NY, USA, 10007 |
| 電話號碼
| +1 212 220-6633 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.definiumtx.com |
| 員工數量
| 106 |
| Ms. Brandi L. Roberts |
Chief Financial Officer and Principal Accounting Officer |
-- |
26/02/2026 |
| Mr. Robert B. Barrow |
Chief Executive Officer and Director |
美元 623.50K |
26/02/2026 |
| Mr. Matthew T. Wiley |
Chief Commercial Officer |
-- |
23/04/2025 |
| Dr. Daniel R. Karlin, M.A.,M.D. |
Chief Medical Officer |
美元 485.50K |
23/04/2025 |
| Mr. Mark R. Sullivan, J.D. |
Chief Legal Officer and Corporate Secretary |
美元 439.75K |
23/04/2025 |
|
|
| Mr. Robert B. Barrow |
Chief Executive Officer and Director |
26/02/2026 |
| Ms. Carol A. Vallone |
Chairman of the Board |
26/02/2026 |
| Mr. Roger Adsett |
Director |
29/01/2026 |
| Mr. David W. Gryska, M.B.A. |
Independent Director |
26/02/2026 |
| Mr. Andreas Krebs |
Vice Chairman of the Board |
26/02/2026 |
| Dr. Roger Crystal, M.D. |
Independent Director |
26/02/2026 |
| Dr. Suzanne L. Bruhn, PhD |
Independent Director |
26/02/2026 |
|
|
|
|
